# Thymosin Alpha-1: Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on thymosin alpha-1 (Zadaxin/thymalfasin) — an immune-calibrating thymic peptide with real human RCTs in hepatitis B, a negative phase 3 sepsis trial, and an unsettled 2026 US legal status.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
Thymosin alpha-1 is, among popular peptides, **unusually well-studied in humans** — and that is precisely why its profile is sobering rather than hyped. It has real RCT and meta-analytic support for a *delayed* virological benefit in chronic hepatitis B (OR about 2.67 at 12 months), a coherent Toll-like-receptor/T-cell mechanism, and a clean tolerability record. But its definitive phase 3 sepsis trial was **negative**, and COVID-19 and general immune-boosting claims rest on retrospective data only. The honest grade is **B**.[4](https://peptidevox.com/#r4)[6](https://peptidevox.com/#r6)

Thymosin alpha-1 (Talpha1; thymalfasin; brand **Zadaxin**) is a naturally occurring 28-amino-acid thymic peptide that acts as a calibrating immunomodulator. It is approved for hepatitis B, hepatitis C and as a cancer immunoadjuvant in more than thirty countries, but it is **not approved by the FDA**.[1](https://peptidevox.com/#r1) Its popularity in wellness and longevity circles is large; its honest human evidence is real but indication-specific. This monograph separates the proven from the hyped.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Thymosin alpha-1 is not FDA-approved in the United States. Dosing figures are reported strictly as seen in the published literature and approved foreign labeling for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is thymosin alpha-1 and how does it work?

Thymosin alpha-1 is a 28-residue, N-acetylated acidic polypeptide (molecular weight about 3,108 Da), identical to the human peptide and produced for therapeutic use by chemical synthesis.[1](https://peptidevox.com/#r1) It is generated in the body by proteolytic cleavage of the precursor prothymosin alpha; its low isoelectric point and acetylated N-terminus give partial protection against aminopeptidase degradation.[1](https://peptidevox.com/#r1)

Mechanistically the peptide is best understood as a **bidirectional immune calibrator** rather than a pure stimulant. Its principal innate-immune mechanism is Toll-like receptor signaling — chiefly TLR9 and TLR2 on dendritic cells and monocytes — engaging MyD88- and TRIF-dependent cascades, NF-kB and p38-MAPK, and driving production of IL-12, IFN-alpha and TNF-alpha.[2](https://peptidevox.com/#r2)[3](https://peptidevox.com/#r3) Downstream it promotes maturation of myeloid and plasmacytoid dendritic cells, enhances antigen presentation, drives CD4+ and CD8+ T-cell maturation with Th1 polarization, augments NK-cell cytotoxicity, and increases type I interferon output.[3](https://peptidevox.com/#r3) A clinically important nuance is context dependence: the same peptide can restore exhausted T-cell compartments in immunosuppressed hosts yet help limit overactivation, which is why authors caution against labeling it purely stimulatory or suppressive.[11](https://peptidevox.com/#r11)[12](https://peptidevox.com/#r12)

The human pharmacokinetics are well characterized. After subcutaneous injection of 0.8 to 6.4 mg, the peptide is rapidly absorbed with a time-to-peak of about 2 hours and a serum half-life of about 2 hours, dose-proportional exposure, return to baseline by 24 hours, and no accumulation with repeated dosing; 31 to 60% is excreted in urine.[1](https://peptidevox.com/#r1) Crucially, the biological effect outlasts the plasma half-life because the peptide induces durable shifts in immune-cell populations — the rationale for twice-weekly rather than daily dosing in chronic indications.[1](https://peptidevox.com/#r1)

## What is the evidence by indication?

Thymosin alpha-1 has genuine human trials, but the strength varies sharply by indication. The table below summarizes the best available evidence for each.

  Thymosin alpha-1 evidence by indication

    IndicationBest evidenceGrade

    Chronic hepatitis BMeta-analysis of 5 RCTs: monotherapy about threefold superior for virological response at 12 months (OR 2.67); combination data strongerB (approaching A)
    Chronic hepatitis CCombination with interferon (approved abroad); largely historical in the direct-acting-antiviral eraB
    Sepsis / severe sepsisDefinitive 1,089-patient phase 3 TESTS RCT negative (HR 0.99); earlier ETASS RCT borderline positiveA evidence, net-negative
    Cancer immunoadjuvant488-patient melanoma phase 2 RCT: modest, mixed immunologic signal, no survival winB
    COVID-19 / acute lung infectionRetrospective cohorts only; no positive RCTB (retrospective)

The strongest human evidence is in **chronic hepatitis B**. A meta-analysis of 5 RCTs (353 participants) found thymosin alpha-1 monotherapy roughly threefold superior to placebo or usual care for virological response at 12 months post-treatment (OR 2.67, 95% CI 1.25 to 5.68), but no significant response at end of treatment or at 6 months — that is, a *delayed* effect.[4](https://peptidevox.com/#r4) A 33-patient head-to-head RCT against interferon-alfa found no significant difference in complete response but markedly better tolerability for the peptide.[5](https://peptidevox.com/#r5) Combination data are stronger still: pooled RCTs found the peptide plus lamivudine, and the peptide plus entecavir, superior to the antiviral alone.[4](https://peptidevox.com/#r4) The caveat is that major hepatology guidelines do not currently include it in standard HBV regimens.[4](https://peptidevox.com/#r4)

The **sepsis** story is the most instructive. The early ETASS RCT showed a borderline 28-day mortality reduction (26.0% vs 35.0%; P=0.049) plus improved monocyte HLA-DR — promising but underpowered.[7](https://peptidevox.com/#r7) The definitive phase 3 TESTS trial, registered as [a 1,089-patient double-blind placebo-controlled study published in the BMJ in 2025](https://pubmed.ncbi.nlm.nih.gov/39814420/), found no benefit: 28-day mortality 23.4% vs 24.1%, hazard ratio 0.99 (95% CI 0.77 to 1.27).[6](https://peptidevox.com/#r6) Exploratory, Bonferroni-uncorrected subgroups hinted at heterogeneity by age and diabetes, but these are hypothesis-generating only.[6](https://peptidevox.com/#r6) Older meta-analyses that predate or exclude TESTS favor the peptide, but they are dominated by smaller, lower-quality trials and are superseded by the negative phase 3 result.[8](https://peptidevox.com/#r8)[9](https://peptidevox.com/#r9)

In **cancer**, the largest trial is a 488-patient randomized phase 2 in metastatic melanoma: tumor responses were numerically higher in the thymosin-containing arms than in the control arm, a positive immunologic signal without a definitive survival win.[10](https://peptidevox.com/#r10) Retrospective propensity-matched data also associate the peptide with improved post-resection survival in HBV-related hepatocellular carcinoma.[14](https://peptidevox.com/#r14) For **COVID-19**, the widely cited Wuhan study retrospectively reviewed 76 severe patients and associated the peptide with reduced mortality and reversal of T-cell exhaustion, with benefit greatest in the most lymphopenic patients; a separate 334-patient retrospective analysis found reduced 28-day mortality.[11](https://peptidevox.com/#r11)[13](https://peptidevox.com/#r13) These are non-randomized and confounding-prone, and contemporaneous commentary urged caution; no positive RCT establishes a COVID-19 benefit.[12](https://peptidevox.com/#r12)

Proven vs hyped
Proven: a delayed virological benefit in chronic hepatitis B and a coherent immune mechanism. Disproven/over-hyped: the 'sepsis lifesaver' framing, which failed the definitive phase 3 TESTS trial (HR 0.99). Unproven: COVID-19 and general longevity immune-boosting claims, which rest on retrospective or mechanistic data only.[6](https://peptidevox.com/#r6)

## What doses appear in the literature?

Reported strictly as information, not a protocol. The approved hepatitis regimen on the Zadaxin label is 1.6 mg (about 900 ug/m2) subcutaneous twice weekly, injections roughly 3 to 4 days apart, for commonly 6 months in HBV, extendable to 12 months in partial responders; the pediatric or low-weight figure is 40 ug/kg.[1](https://peptidevox.com/#r1) The product is a single-use vial of lyophilized peptide reconstituted with sterile water immediately before use, and the label specifies the subcutaneous route only — not for IV use.[1](https://peptidevox.com/#r1) Sepsis trials used a more intensive short course: TESTS dosed every 12 hours for 7 days.[6](https://peptidevox.com/#r6)[7](https://peptidevox.com/#r7) Cancer trials used 1.6 to 6.4 mg subcutaneous in combination schedules, with the 3.2 mg arms carrying the strongest signal in the melanoma RCT.[10](https://peptidevox.com/#r10) The pharmacokinetic rationale for twice-weekly chronic dosing is the roughly 2-hour half-life paired with durable downstream immune effects.[1](https://peptidevox.com/#r1)

## How safe is thymosin alpha-1?

Across indications the peptide is described as well tolerated, with under 1% drug-related adverse events; reported effects are infrequent and mild — injection-site discomfort or erythema, rash, and rare reports of transient muscle atrophy and polyarthralgia with hand edema.[1](https://peptidevox.com/#r1) In hepatitis B RCTs the only commonly reported issue was local injection-site discomfort, contrasting with the systemic toxicity of interferon, and the ETASS and TESTS sepsis RCTs recorded no serious drug-related adverse events.[5](https://peptidevox.com/#r5)[6](https://peptidevox.com/#r6) The contextual concerns are immunologic: because the peptide amplifies Th1, CD8 and dendritic-cell activity, the FDA's compounding evaluation flagged general peptide concerns around immunogenicity and uncharacterized immune effects for unapproved bulk material.[16](https://peptidevox.com/#r16) The TESTS subgroup signal of possible higher mortality in younger sepsis patients is a reminder that immune modulation is context-dependent and not uniformly benign.[6](https://peptidevox.com/#r6) Contraindications include known hypersensitivity, a relative contraindication in deliberate immunosuppression such as transplant recipients, and pregnancy Category C.[1](https://peptidevox.com/#r1)

## What is the FDA and WADA status in 2026?

Thymosin alpha-1 is not FDA-approved for any indication in the United States, though it holds four orphan-drug designations, none of which has led to approval; it is approved abroad as Zadaxin or thymalfasin in more than thirty countries.[1](https://peptidevox.com/#r1)[16](https://peptidevox.com/#r16) The compounding timeline is precise: in September 2023 the FDA placed the peptide, with about 18 others including BPC-157 and TB-500, into 503A Category 2, effectively barring compounding-pharmacy use, prompting litigation against the agency.[15](https://peptidevox.com/#r15)[17](https://peptidevox.com/#r17) On September 20, 2024 the FDA removed thymosin alpha-1 from Category 2 after the nominators withdrew their nominations, and referred it to the Pharmacy Compounding Advisory Committee.[15](https://peptidevox.com/#r15) Net effect in 2026: the peptide is off Category 2 but not affirmatively listed or approved for compounding — a regulatory gray zone pending PCAC, with final determinations anticipated late 2026 to early 2027.[16](https://peptidevox.com/#r16)

For athletes the picture differs from its more notorious cousin. Thymosin alpha-1 is not explicitly named on the WADA Prohibited List, a key distinction from thymosin beta-4 (TB-500), which is explicitly prohibited at all times under category S2.3 — the two should never be conflated.[18](https://peptidevox.com/#r18) That said, athletes should weigh the broad S2 language covering other growth factors and modulators, and the list governs only substances under WADA-signatory testing; the peptide has not been studied for athletic performance in any case.[19](https://peptidevox.com/#r19)

**Bottom line.** Thymosin alpha-1 is a real, approved drug abroad with a clean tolerability record and genuine human evidence — but that evidence is indication-specific. From a root-cause, immune-restoration lens it is most plausible specifically in measurably immunocompromised or lymphopenic states, not as a casual immune booster. The honest grade is B, not A, outside hepatitis B, and not a license for self-administration of unapproved material. Regulatory facts here are current as of June 2026 and should be re-verified after the next PCAC review.

---
Source: https://peptidevox.com/peptide-encyclopedia/thymosin-alpha-1
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt